Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

4.04
+0.06001.51%
Post-market: 4.040.00000.00%17:15 EDT
Volume:202.27K
Turnover:816.80K
Market Cap:227.99M
PE:-2.41
High:4.18
Open:3.97
Low:3.93
Close:3.98
Loading ...

Astria Therapeutics Announces Design of Alpha-Orbit Pivotal Phase 3 Trial of Navenibart in Hae

THOMSON REUTERS
·
13 Jan

Astria Therapeutics Inc - Phase 3 Initiation Expected in Q1 2025

THOMSON REUTERS
·
13 Jan

Astria Therapeutics Inc: Alpha-Orbit Top-Line Results Anticipated in Early 2027.

THOMSON REUTERS
·
13 Jan

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Jan

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Benzinga
·
23 Dec 2024

Top Premarket Decliners

MT Newswires Live
·
16 Dec 2024

Astria Therapeutics announces final results from ALPHA-STAR trial

TIPRANKS
·
11 Dec 2024

Astria Therapeutics: Advancing Navenibart to Phase 3 Development With Trial Initiation Expected in Q1 2025

THOMSON REUTERS
·
11 Dec 2024

Astria Therapeutics Inc - Navenibart Shows Favorable Safety and Well-Tolerated Profile

THOMSON REUTERS
·
11 Dec 2024

Astria Therapeutics Announces Positive Final Results From Target Enrollment in the Alpha-Star Phase 1B/2 Trial of Navenibart for Hae

THOMSON REUTERS
·
11 Dec 2024

Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Astria Therapeutics announces FDA clearance for STAR-0310 IND application

TIPRANKS
·
10 Dec 2024

BRIEF-Astria Therapeutics Announces FDA Clearance Of IND Application For STAR-0310

Reuters
·
10 Dec 2024

Astria Therapeutics Inc: Early Proof-of-Concept Results Expected in Q3 2025

THOMSON REUTERS
·
10 Dec 2024

Astria Therapeutics Announces FDA Clearance of Ind Application for Star-0310, a Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis

THOMSON REUTERS
·
10 Dec 2024

Astria Therapeutics Inc: Phase 1a Trial of Star-0310 in Healthy Volunteers Expected to Initiate in Q1 2025

THOMSON REUTERS
·
10 Dec 2024

BRIEF-Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Dec 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Dec 2024

TD Cowen Reaffirms Their Buy Rating on Astria Therapeutics (ATXS)

TIPRANKS
·
20 Nov 2024

Oppenheimer Adjusts Astria Therapeutics Price Target to $28 From $26, Maintains Outperform Rating

MT Newswires Live
·
14 Nov 2024